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ABSTRACT
Objective  An interim analysis of an all-patient 
postmarketing surveillance programme in Japan to 
investigate the safety of tocilizumab for the treatment of 
rheumatoid arthritis (RA) in the real world.
Methods  This analysis included 3881 patients. Patients 
received 8 mg/kg of tocilizumab every 4 weeks, and were 
observed for 28 weeks. Data on baseline characteristics 
and adverse events (AE) were collected.
Results  Total and serious AE were reported as 167 
and 27 events/100 patient-years, respectively. The most 
frequent AE and serious AE were infections. Logistic 
regression analysis identiﬁ  ed the following risk factors 
for the development of serious infection: concurrent or 
medical history of respiratory disorders; prednisolone 
dose at baseline ≥5 mg/day; and age ≥65 years. 
Twenty-ﬁ  ve patients died, and the standardised mortality 
ratio, with the Japanese general population in 2008 
as reference, was 1.66, similar to the results from the 
Japanese cohort study for RA patients.
Conclusions  Tocilizumab is acceptably safe in the 
real clinical setting. Tocilizumab needs to be used with 
consideration of the beneﬁ  t–risk balance to avoid serious 
infections in elderly patients and those on high doses of 
corticosteroids or with a concurrent or medical history of 
respiratory disorders.
Tocilizumab is a humanised anti-human interleu-
kin 6 receptor monoclonal antibody. On the basis 
of previous clinical studies1–7 it was approved in 
Japan as an antirheumatic drug in 2008, and was 
subsequently approved in Europe in 2009 and in 
the USA in 2010.
The main objectives of all-patient postmarket-
ing surveillance (PMS) programmes are to assess a 
drug’s safety proﬁ  le in the real world, to identify 
any risk factors for adverse events (AE) or adverse 
reactions, and also to verify effectiveness.
The PMS for tocilizumab was conducted from 
April 2008 to November 2009 as one of the con-
ditions for approval in Japan, and a total of 8527 
patients were enrolled. We report here the results of 
an interim safety analysis of 3881 registered patients 
who had completed 28 weeks of tocilizumab obser-
vation between April 2008 and July 2009.
METHODS
Patients
The PMS was conducted on all rheumatoid arthritis 
(RA) patients who received tocilizumab during the 
surveillance period in Japan. Tocilizumab was given 
to patients who showed inadequate response to at 
least one non-biological disease-modifying antirheu-
matic drug and who conformed to the Japan College 
of Rheumatology guidelines for tocilizumab8 (see 
supplementary text S1, available online only). Patients 
also had to be screened for tuberculosis based on an 
interview, a tuberculin skin test and a chest x-ray 
before initiation of tocilizumab treatment.
Protocol
Patient registration was controlled centrally (see 
supplementary text S2, available online only). 
Patients received an intravenous infusion of 8 mg/
kg of tocilizumab every 4 weeks. The observation 
period was from the initiation of tocilizumab treat-
ment (week 0) to week 28. Data collected included 
baseline patient characteristics and all AE occurring 
during the 28 weeks or within 4 weeks of the last 
tocilizumab infusion.
Statistical analysis
AE were classiﬁ   ed using system organ classes 
and preferred terms according to MedDRA v12.0. 
Univariate logistic analysis was used to screen 
for potential predictive variables, and a stepwise 
selection process was used for the multivariate 
regression model for identifying the risk factors for 
serious infections, interstitial lung disease (ILD), 
hepatic function abnormalities, cardiac disor-
ders and death. The standardised mortality ratio 
was calculated relative to mortality in the general 
Japanese population in 2008.9 p values below 0.05 
were considered signiﬁ  cant.
RESULTS
Patient demographics
In this interim report, 3881 RA patients were anal-
ysed (total exposure 1793.5 patient-years; mean 
observation period (SD) 24.1 (7.4) weeks) (see sup-
plementary table S1 and supplementary text S3, 
available online only).
Overall safety
A total of 3004 AE in 1641 patients (167.4/100 
patient-years) and 490 serious adverse events 
(SAE) in 361 patients (27.3/100 patient-years) 
were reported. For 2330 AE in 1379 patients 
(129.9/100 patient-years) and 363 SAE in 278 
patients (20.2/100 patient-years), it was judged 
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history of ILD, and an infection was a trigger for the onset of 
interstitial pneumonia in three patients.
Fifteen malignancies were reported in 15 patients (0.84/100 
patient-years). At present, no speciﬁ  c patterns have been identi-
ﬁ  ed in terms of the types of malignancies.
Seven gastrointestinal perforations were reported in six 
patients (0.39/100 patient-years); in all cases, perforation 
occurred before the ﬁ  fth dose of tocilizumab. All these patients 
had acute abdominal pain at onset and recovered with appropri-
ate intervention including intestinal resections.
Death was reported in 25 patients (see supplementary table 
S2, available online only). The standardised mortality ratio was 
1.66 (95% CI 1.12 to 2.46), which was similar to the results 
reported in the Japanese cohort study for RA.9
Signiﬁ  cant risk factors identiﬁ  ed for serious infections were 
age 65 years or greater, a concurrent or medical history of 
respiratory disease and corticosteroid dosage of 5 mg/day or 
greater (prednisolone equivalent) at the baseline; risk factors 
for ILD were a concurrent or medical history of ILD and age 
65 years or greater; risk factors for serious cardiac function 
disorders were a concurrent or medical history of cardiac func-
tion disorders and low bodyweight (<40 kg); risk factors for 
hepatic function disorders were a concurrent hepatic function 
disorder and the concomitant use of methotrexate; and risk 
that a causal relationship with tocilizumab could not be ruled 
out and these were classiﬁ  ed as adverse drug reactions (ADR). 
The most common AE and SAE were infections and infesta-
tions (table 1).
Clinically important AE
The most common serious infection was pneumonia (47 events 
in 44 patients; 2.62/100 patient-years). Five patients (0.28/100 
patient-years) developed sepsis or septic shock (table 2).
Four patients developed tuberculosis (0.22/100 patient-years). 
None of these patients had a history of tuberculosis. Two cases 
developed after more than 4 months of tocilizumab treatment, 
and the other two cases developed 24 days and 78 days after 
the beginning of tocilizumab infusion. All cases improved with 
appropriate treatment.
Twelve serious hepatobiliary disorders were reported in 11 
patients (0.67/100 patient-years). No hepatitis B/C-positive 
patients or hepatitis B/C virus carriers developed hepatobiliary 
disorders.
Twenty-ﬁ   ve serious cardiac disorders were reported in 24 
patients (1.39/100 patient-years). Of these patients, 13 (54.2%) 
had a concurrent or medical history of cardiac disturbance.
Twenty-three ILD events were reported in 23 patients 
(1.28/100 patient-years); 13 patients had a concurrent or medical 
Table 1  The incidence rate (events/100 patient-years) of AE and ADR classiﬁ  ed by SOC in RA patients 
treated with tocilizumab
Total AE Serious AE Total ADR Serious ADR
No of events No of events No of events No of events
SOC  (/100 patient-years)  (/100 patient-years)  (/100 patient-years)  (/100 patient-years)
Total 3,004 (167.49) 490 (27.32) 2,330 (129.91) 363 (20.24)
Infections and infestations 553 (30.83) 163 (9.09) 447 (24.92) 147 (8.20)
Laboratory test abnormalities 636 (35.46) 39 (2.17) 563 (31.39) 36 (2.01)
Hepatobiliary disorders 269 (15.00) 12 (0.67) 213 (11.88) 11 (0.61)
Skin and subcutaneous tissue 
disorders
247 (13.77) 6 (0.33) 205 (11.43) 6 (0.33)
Gastrointestinal disorders 221 (12.32) 42 (2.34) 145 (8.08) 30 (1.67)
Respiratory, thoracic and 
mediastinal disorders
207 (11.54) 37 (2.06) 150 (8.36) 26 (1.45)
Metabolism and nutrition 
disorders
172 (9.59) 4 (0.22) 159 (8.87) 3 (0.17)
General disorders and 
administration site conditions
145 (8.08) 18 (1.00) 124 (6.91) 16 (0.89)
Musculoskeletal and connective 
tissue disorders
135 (7.53) 20 (1.12) 87 (4.85) 12 (0.67)
Nervous system disorders 102 (5.69) 21 (1.17) 70 (3.90) 13 (0.72)
Blood and lymphatic system 
disorders
64 (3.57) 23 (1.28) 51 (2.84) 19 (1.06)
Vascular disorders 63 (3.51) 13 (0.72) 33 (1.84) 7 (0.39)
Injury, poisoning and procedural 
complications
53 (2.96) 34 (1.90) 5 (0.28) 3 (0.17)
Cardiac disorders 45 (2.51) 25 (1.39) 33 (1.84) 17 (0.95)
Renal and urinary disorders 21 (1.17) 5 (0.28) 12 (0.67) 3 (0.17)
Eye disorders 20 (1.12) 1 (0.06) 10 (0.56) 1 (0.06)
Neoplasms benign, malignant 
and unspeciﬁ  ed (including cysts 
and polyps)
18 (1.00) 15 (0.84) 7 (0.39) 5 (0.28)
Psychiatric disorders 11 (0.61) 2 (0.11) 2 (0.11) 0 (0.00)
Immune system disorders 8 (0.45) 7 (0.39) 8 (0.45) 7 (0.39)
Ear and labyrinth disorders 6 (0.33) 2 (0.11) 3 (0.17) 1 (0.06)
Endocrine disorders 4 (0.22) 1 (0.06) 1 (0.06) 0 (0.00)
Reproductive system and breast 
disorders
4 (0.22) 0 (0.00) 2 (0.11) 0 (0.00)
ADR, adverse drug reaction; AE, adverse event; RA, rheumatoid arthritis; SOC, Medical Dictionary for Regulatory Activities (MedDRA) 
system organ class (MedDRA v12.0).
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DISCUSSION
In this interim analysis, the safety proﬁ   le of tocilizumab in 
Japanese RA patients in the real world was clariﬁ  ed.
The most common AE and SAE reported in this analysis were 
infections and infestations. The incidence rate of infections as 
SAE was higher in this report (9.1/100 patient-years) than in 
the tocilizumab clinical study in Japan (6.2/100 patient-years)10 
or in other tocilizumab global clinical studies.1–7 In this PMS, 
all patients were enrolled including those who had risk factors 
for serious infections, and all AE were monitored after initiat-
ing treatment. In the clinical trials, on the other hand, although 
the incidence rate of reported AE is accurate because all AE are 
recorded, patients were excluded for a number of conditions 
including risk factors for serious infection. These factors might 
make a difference between this PMS and clinical studies in the 
incidence rates of serious infections.
Although there was no parallel control study and patient back-
ground might be not comparable, in terms of infections as serious 
ADR our results (8.20/100 patient-years; 3.4%) were equivalent 
to the results of 6 months’ inﬂ  iximab PMS data (8.56/100 patient-
years)11 and higher than 6 months’ etanercept PMS data (2.4%) 
(PMS report www.enbrel.jp/member/report/kansetsu_7.html). 
These results suggest that, in common with other anti-tumour 
necrosis factor (TNF) biological agents, careful monitoring of 
signs and symptoms of infection is important during treatment 
with tocilizumab to avoid the development of serious infections, 
especially in patients with identiﬁ  ed risk factors.11 12
The reactivation of tuberculosis is a major concern during 
anti-TNF treatment, but there is no medical consensus regarding 
the effect of interleukin 6 signal inhibition on tuberculosis.13 14 
Therefore, all patients were screened for tuberculosis in the 
same way as those receiving anti-TNF treatments, and chemo-
prophylaxis was provided as needed before starting tocilizumab 
treatment. As a result, the incidence rate of tuberculosis in this 
study (0.1%, 0.22/100 patient-years) was equivalent to that in 
the PMS of inﬂ  iximab (0.3%) and etanercept (0.1%).11 12 Because 
tuberculosis developed in various periods after the initiation of 
tocilizumab treatment, the collection of case reports and further 
detailed study will be needed to clarify the risk factors for tuber-
culosis developing during tocilizumab treatment.
ILD was reported more frequently in this PMS study than 
in the clinical studies,10 but the incidence rate of this AE was 
equivalent to that found in the PMS of inﬂ  iximab and etanercept 
in Japan.11, 12 As infection is a trigger for the onset of interstitial 
pneumonia, careful monitoring of infection will be mandatory 
in patients with a concurrent or medical history of ILD.
Serious hepatic function disorders through the reactivation 
of hepatitis virus were not reported in this study. Nevertheless, 
tocilizumab treatment of patients infected with hepatitis virus 
(ie, hepatitis virus carriers or patients with viral hepatitis) is not 
recommended at present because there is limited experience with 
tocilizumab treatment in these patients, and because the reacti-
vation of hepatitis B was reported during anti-TNF   therapy.15 
Moreover, because the concomitant use of methotrexate was 
shown to be a risk factor for hepatic function disorders, hepatic 
function should be periodically tested when tocilizumab is used 
with methotrexate.
As a concurrent or medical history of cardiovascular disorders 
and low bodyweight are risk factors for developing cardiovascu-
lar disease, careful monitoring is needed in these patients.
Anaphylaxis was reported in seven patients (0.4/100 patient-
years). All of these cases were reported before the fourth infusion 
of tocilizumab. Therefore, careful monitoring for anaphylaxis is 
required in the early phase of tocilizumab treatment.
factors for death were age 65 years or greater, a concurrent or 
medical history of cardiac disorders, concurrent renal impair-
ment and Steinbrocker class 3 or 4 (table 3 and supplementary 
text S4, available online only). Although serum total choles-
terol was increased to greater than 300 mg/dl in 100 patients 
(2.6%) and triglycerides were increased to greater than 375 
mg/dl in 70 patients (1.8%), no patients who showed these 
abnormalites continuously developed serious cardiac function 
disorders.
Table 2  Common SAE in tocilizumab-treated RA patients
No of events
    (/100 patient-years)
Total 490 (27.3)
Infections and infestations 163 (9.09)
 Pneumonia* 47 (2.62)
 Cellulitis 19 (1.06)
 Herpes  zoster 11 (0.61)
  Atypical mycobacterial infection 9 (0.50)
  Arthritis bacterial and arthritis infective 9 (0.50)
 Diverticulitis 6 (0.33)
 Pneumocystis  jiroveci pneumonia 5 (0.28)
  Sepsis and septic shock 5 (0.28)
 Gastroenteritis 5 (0.28)
 Tuberculosis† 4 (0.22)
 Bronchitis 4 (0.22)
 Pyelonephritis 4 (0.22)
Malignancies 15 (0.84)
 Breast  cancer 2 (0.11)
 Gastric  cancer 2 (0.11)
 B-cell  lymphoma 1 (0.06)
  Basal cell carcinoma 1 (0.06)
  Bile duct cancer 1 (0.06)
 Bladder  neoplasm 1 (0.06)
 Lymphoma 1 (0.06)
 Meningioma 1 (0.06)
 Pleural  mesothelioma 1 (0.06)
 Uterine  cancer 1 (0.06)
  Large intestine carcinoma 1 (0.06)
 Cervix  carcinoma 1 (0.06)
 Lung  neoplasm 1 (0.06)
Others
  Cardiac function disorder 25 (1.39)
  ILD and organising pneumonia 23 (1.28)
  White blood cell count decreased 15 (0.84)
 Hepatobiliary  disorder 12 (0.67)
  Neutrophil count decreased 10 (0.56)
  Anaphylactic reaction, anaphylactic shock, 
    anaphylactoid reaction and hypersensitivity
7 (0.39)
 Fever 7 (0.39)
 Gastrointestinal  perforation‡ 7 (0.39)
 Melaena 7 (0.39)
 Neutropenia 6 (0.33)
  Acute myocardial infarction 6 (0.33)
 RA 6 (0.33)
  Vertebral compression fracture 6 (0.33)
 Cerebral  infarction 5 (0.28)
 Pneumothorax 5 (0.28)
 Leucopenia 5 (0.28)
  Disseminated intravascular coagulation 4 (0.22)
 Arthralgia 4 (0.22)
*Pneumonia: includes bronchial pneumonia, lobar pneumonia, pneumonia, mycoplasmal 
pneumonia, primary atypical pneumonia, bacterial pneumonia and pneumococcal 
pneumonia.
†Tuberculosis: pulmonary tuberculosis in three of the patients and peritoneal 
tuberculosis in one.
‡Gastrointestinal perforations: includes appendicitis perforated, gastric perforation, 
intestinal perforation, large intestinal perforation, and small intestinal perforation.
ILD, interstitial lung disease; RA, rheumatoid arthritis; SAE, serious adverse event.
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In conclusion, these results show that tocilizumab was well 
tolerated and the safety of tocilizumab is within an acceptable 
range in the real clinical setting. Because this surveillance was 
conducted only 28 weeks, a long-term surveillance programme 
is also currently underway to clarify the long-term safety of 
tocilizumab in daily clinical practice in Japan.
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